Semaglutide on NHS England: What the Current Guidance Means for You

Does NHS England prescribe semaglutide for weight loss?

Yes, but with significant caveats. NHS England funds semaglutide as Wegovy for weight management under NICE technology appraisal TA875, published in March 2023. The appraisal recommends it for adults with a BMI of 35 or above alongside at least one weight-related health condition, or for those who fall just below that threshold and have been referred to specialist care. Lower BMI thresholds apply for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, typically 2.5 kg/m² lower throughout.

There is, though, a structural constraint that catches most people out: NHS England requires treatment to be delivered within a specialist weight management service that includes multidisciplinary support. That rules out a straightforward GP prescription in most cases. NICE also specifies that treatment should be reconsidered if less than 5% of body weight is lost after six months at the full maintenance dose, and that it should not continue beyond two years under the NHS framework. Those conditions are binding for NHS supply, they don't apply if you access semaglutide privately, where the prescriber makes an individual clinical assessment.

Scotland operates its own separate criteria. If you're based north of the border, the picture is different, you can find a breakdown of the Scottish NHS semaglutide position separately.

Who actually qualifies under NHS England's criteria right now?

Qualifying on paper and getting timely access are two different things. The NICE criteria set the clinical floor, but NHS England has layered its own phased commissioning guidance on top, which shapes what's actually available at any given time.

For tirzepatide (Mounjaro), the NHS phased rollout is more explicitly structured. Semaglutide as Wegovy sits differently: it is commissioned through specialist weight management services, and those services carry waiting lists that, in many parts of England, stretch to months or longer. A GP can refer you, but neither the referral nor meeting the criteria means treatment starts soon.

There is also a practical geography problem. Not every integrated care board has equally resourced specialist services. Where you live genuinely affects how quickly you can access NHS-funded treatment, and our guide to semaglutide on the NHS walks through what the commissioning pathway means in practice, including what wraparound care is required. For a detailed look at how NHS England handles the semaglutide pathway the NHS England Wegovy access page covers the commissioning detail.

If your BMI sits between 27 and 34.9 with a weight-related condition, you may be licensed to use semaglutide privately but not meet the NHS England threshold. That gap is where many people find themselves.

What is semaglutide actually licensed for on the NHS in England?

This question matters because semaglutide comes under several brand names with different licences, and conflating them causes real confusion. Wegovy (the 2.4mg weekly injection) is the one licensed for weight management. Ozempic is also semaglutide but holds a UK licence for type 2 diabetes, not weight loss; the NHS will not fund Ozempic off-label for obesity, and it should never be sought for that purpose. More recently, the MHRA approved a dedicated 7.2mg Wegovy pen for adults with obesity (BMI 30 or above), though the NHS has not yet commissioned it through a funded pathway. Separately, an oral semaglutide tablet (Wegovy tablets) gained MHRA approval in June 2026 for weight management, again, without an NHS funding route at this stage.

The NHS medicines information page for semaglutide on the NHS covers the patient-level detail of how it works, what side effects to expect, and when to seek medical advice. It's worth reading before your consultation, whichever route you're considering.

One thing worth knowing: the oral tablet form needs to be taken first thing in the morning on an empty stomach, waiting at least 30 minutes before any food or drink including your morning coffee. It's a meaningful daily commitment that some people prefer to plan around before starting. Whether the injection or tablet format suits you better is a clinical and practical question your prescriber can help with.

What are the alternatives if NHS England won't fund semaglutide for you?

A private prescription is the main route for people outside the NHS criteria or unwilling to join a waiting list. The licensed eligibility for private prescribing is broader than the NHS threshold: adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes or obstructive sleep apnoea. If you want to understand exactly what that private route involves, our page on how to purchase semaglutide through a regulated provider explains the steps and what to expect from a legitimate clinical assessment.

Private treatment carries a cost. For context on what that looks like, the guide to buying Wegovy privately gives honest pricing background. It's also worth understanding the safety requirements that any legitimate private provider must meet, prescription-only medicines cannot lawfully be supplied without a clinical assessment, regardless of the platform. Before using any online pharmacy, checking it on the GPhC register takes under a minute and tells you whether it is regulated. If you are ready to move forward, our guide to buying semaglutide safely covers what a proper online consultation should involve and how to avoid unsafe sellers. Sellers offering these medicines without a clinical review are a safety risk, not just a regulatory one.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber (a real clinician, reading your answers) before any prescription is issued. Our clinical team is set up to assess both Wegovy and tirzepatide. If you'd like to explore whether treatment is right for you, starting a free consultation is the first step.